Cutera announces the international limited commercial release of aviclear® at imcas world congress 2024

Brisbane, calif.--(business wire)--cutera, inc. (nasdaq: cutr), a leading provider of aesthetic and dermatology solutions, announced the international limited commercial release of aviclear, the first energy-based device fda-cleared for the long-term treatment of mild, moderate, and severe acne. aviclear received an enthusiastic reception at this year's international master course on aging science (imcas) conference in paris, france, held february 1-3. aviclear is a 1726nm laser, which targets.
CUTR Ratings Summary
CUTR Quant Ranking